Sucampo Announces First Quarter 2016 Earnings Call

ROCKVILLE, Md., April 20, 2016 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ: SCMP), a global biopharmaceutical company, today announced that it will host its first quarter 2016 financial results teleconference and webcast at 8:30 a.m. Eastern on Wednesday, May 4th. The press release announcing the financial results and operating highlights is expected to be released before the opening of capital markets that day.

Individuals interested in accessing the live audio webcast of the teleconference may do so at http://www.sucampo.com/investors/events-presentations/ and should log on 10 to 15 minutes before the teleconference begins to download any software required. Presentation slides will be available via the webcast link. A replay of the webcast will also be available on Sucampo’s website for several days after the live event. Alternatively, individuals may dial 888-610-7449 (domestic) or 484-747-6634 (international) and use passcode 86905416. A replay of the teleconference will be available by dialing 855-859-2056 (domestic) or 404-537-3406 (international), passcode 86905416, approximately two hours after the teleconference concludes. The archive of the teleconference will be available for 30 days.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K. For more information, please visit www.sucampo.com.

The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).

Twitter   LinkedIn

Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
[email protected]

Source: Sucampo Pharmaceuticals Inc

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Jefferies bullish on Deckers Outdoor, sees HOKA growth slowdown as oversold
• Jefferies Upgrades Friedrich Vorwerk Group SE (VH2:GR) to Hold